azd3759
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 5, 2014 (NCT02228369)
Timeline
Indications
Mechanism of action
FLT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd3759
- azd3759
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03653546 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2018 | Alpha Biopharma (Jiangsu) Co., Ltd., Chinese Academy of Medical Sciences, Shantou University, Sungkyunkwan University |
| NCT03574402 | Phase 2 | Jul 1, 2018 | Guangdong Association of Clinical Trials |
| NCT03360929 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2017 | Shantou University, Tigermed Consulting Co., Ltd |
| NCT02228369 | Phase 1 | Nov 5, 2014 | AstraZeneca |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shantou University | Academic/Hospital | 2 | 0 | 2 | 2017 |
| Alpha Biopharma (Jiangsu) Co., Ltd. | For profit | 1 | 1 | 1 | 2018 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2014 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Guangdong Association of Clinical Trials | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 1 | 1 | 2017 |
7 organizations
Page 1 / 1